EP1150942A1 - Improved compounds for protein binding - Google Patents
Improved compounds for protein bindingInfo
- Publication number
- EP1150942A1 EP1150942A1 EP00904701A EP00904701A EP1150942A1 EP 1150942 A1 EP1150942 A1 EP 1150942A1 EP 00904701 A EP00904701 A EP 00904701A EP 00904701 A EP00904701 A EP 00904701A EP 1150942 A1 EP1150942 A1 EP 1150942A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound according
- group
- membrane
- substitute sheet
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Definitions
- the present invention relates to novel binding compounds, in particular protein binding compounds.
- novel compounds are particularly useful for binding proteins to surface including membranes.
- the present invention provides biosensors incorporating these protein binding compounds.
- the present invention also extends to intermediate compounds for use in the synthesis of the binding compounds of the present invention.
- Ternaiy metal complexes are well known in the literature (1) and can be described as the coordination of two discrete metal chelating groups to a metal.
- the metals normally observed in ternary complexes are Co 2+ , Ni 2+ , Cu 2+ , Zn 2+ .
- Typical metal coordinating groups are nitrilotriacetic acid (NT A), iminodiacetic acid (IDA), catechols, and aromatic nitrogen containing heterocycles such as imidazole.
- Ternary complexes have been characterised by numerous methods including potentiometric calculations (2) and X-ray crystallography (3). These studies have allowed the stability of simple ternary complexes to be determined with the average stability constant (Ka) being 10 3 -lu 4 M '1 (4).
- IMAC Immobilised Metal Affinity Chromatography
- the stability of the ternary complex i.e. the interaction between the metal chelate the metal and the protein, is often too weak for proteins to be immobilised for a sufficiently long period for observation and study.
- the metal chelates employed interact in a non-specific manner with other non-tagged proteins.
- the ternary complexes can be broken down in the presence of certain interferents at concentrations not unknown in certain assay systems.
- the present inventors have developed compounds with improved characteristics to those compounds already disclosed in the literature. These compounds possess a plurality of metal-chelating groups covalently linked. The compounds can be used to attach proteins to materials and surfaces.
- the present invention consists in a compound, the compound having the general Formula I
- Y is a branching moiety and Z represents a polydentate ligand chelating agent that coordinates a metal ion; and n is an integer of at least 2, preferably from 2 to 9.
- Z may be a polydentate ligand that coordinates a metal ion such as Co 2+ , Ni 2+ , Cu 2+ , Zn 2+ .
- the donor atoms of Z may be ⁇ - donor atoms or ⁇ - donor atoms.
- the donor atoms may be selected from N, O, S, P and Si.
- the donor atoms are N.
- Z may be bidentate, tridentate (for example IDA) or quadradentate (for example NTA).
- Z is other than a cyclic or polycyclic.
- Z is a quadradentate ligand such as NTA.
- Y provides at least three moieties for covalent attachment directly, or indirectly through an optional linking group, to Z.
- the backbone of branching group Y may be a residue of a compound, an oligomer or a polymer.
- the linking group has a linear backbone.
- the present invention provides a compound of formula II
- X may be hydrophilic, hydrophobic or have both hydrophobic and hydrophilic regions.
- X may be or include a substituted or unsubstituted alkyl, optionally interrupted by one or more heteroatoms (eg 0, N, S or combinations of two or more thereof), for example oligoethylene glycol or other oligoalkylene
- X may be, or include, a lipid.
- the lipid may be a membrane spanning lipid (MSL).
- MSL membrane spanning lipid
- X includes an hydrophilic region, for example polyalkylene oligomer, and an hydrophobic region, for example a lipid, wherein X is attached to Y via an hydrophobic region optionally via a spacer.
- the present invention provides a compound of Formula III
- X, Y, Z and n are as described above and W is a group that allows for attachment to other molecules, or attachment to surfaces, or insertion into membrane(s).
- W is a group which allows for attachment to other molecules including polymers such as Sepharose (such as an amine functional group, a carboxylic acid functional group, an alcohol functional group, a halide functional group) or attachment to surfaces (such as a thiol or disulfide for attachment to gold or other coinage metal surfaces, or such as a silane derivative for attachment to oxide surfaces) or insertion into membranes (such as a lipid group, or a membrane soluble protein, such as gramicidin). W may also be a group which enables non-covalent attachment such as biotin to streptavidin.
- polymers such as Sepharose (such as an amine functional group, a carboxylic acid functional group, an alcohol functional group, a halide functional group) or attachment to surfaces (such as a thiol or disulfide for attachment to gold or other coinage metal surfaces, or such as a silane derivative for attachment to oxide surfaces) or insertion into membranes (such as a lipid group, or a membrane soluble
- Y is a branching moiety that provides a plurality of moieties for covalent attachment of Z and a single moiety for covalent attachment of X.
- Non-limiting illustrative examples of Y include: amino-polyols such as TRIS, bis-homotris
- amino acids such as 3,5-diaminobenzoic acid, 5-aminoisophthalic acid,
- Substitute Sheet peptides which possess multiple free acid and/or amine moieties, for example
- Y is a branching moiety where there is a plurality of moieties for covalent attachment of Z and X.
- Non-limiting illustrative examples of Y include:
- polyamines such as spermjdine, spermine, pentaethylenehexamine
- polyacids such as tartaric acid, trimesic acid, citric acid, Kemp's triacid
- polyhydroxylated materials such as sugars
- dendrons such as the commercially available “Starburst” compounds
- nucleophiles such as halides, tosylates
- groups to which nucleophiles readily add such as , ⁇ -unsaturated ketones
- the compounds of the present invention may have a wide range of uses. In particular they are useful for the attachment of proteins and other biological macromolecules to surfaces. As will be understood this is a requirement of a multitude of sensing devices and assays.
- Biosensors are well known in the art and are described in PCT/AU93/00620, PCT/AU96/00482, PCT/AU95/00763,
- biosensors there is provided a membrane which includes ionophores and receptors. Binding of an analyte to the receptors causes a detectable change in the conductance or impedance of the membrane.
- receptors directed against the analyte of interest are attached to the ionophore and to the membrane.
- the receptors are proteins such as antibodies or antigen binding fragments thereof such as Fab'. It is believed that the binding compounds of the present invention will be useful in the attachment of such receptors to the ionophores and membrane of the biosensors.
- FIG. 1 Binding of 6His.Rubisco to Jl.triNTA chip. 100, 200 and 400 nM binding curves shown (bottom to top). Binding curves are the responses from Fc2 (control, -Ni 2+ ) subtracted from Fcl.
- Binding of 6His.CD40 to Jl.triNTA chip 100, 200, 400, 600 and 800 nM binding curves shown (bottom to top). Binding curves are the responses from Fc2 (control, -Ni 2+ ) subtracted from Fcl.
- Binding of 6HIS.CD40 to triNTA has a 12 fold higher affinity than to NTA. This is mainly as a result of a 10-fold higher on rate (k .
- the off rate (k for the NTA binding is likely to be exaggerated.
- N6-carbobenzyloxy-L-lysine,2-tTimethylsilylethanol, l-(3-dimethylaminopropyl)-3- ethylcarbodiiuiide hydrochloride (EDC), dicyclohexylcarbodiimide (DCC), N- hydroxysuccinamide (NHS) and 6-aminocaproic acid (X) were obtained from Sigma- Aldrich chemical company.
- XXBoc was prepared by reacting XBoc NHS ester (itself obtained by protection of the amino group of X with BocON under standard conditions, and subsequent coupling with NHS using DCC) with X.
- Dichloromethane was distilled over P 2 O 5 immediately prior to use.
- Substitute Sheet 25 ml was added dropwise to the reaction mixture over 2 h. The solution was allowed to warm to room temperature and stirred at room temperature overnight. The reaction mixture was heated at 50°C for 2 h, then allowed to cool to room temperature. An aqueous solution of HC1 (IM, 40 ml) was added dropwise to the reaction mixture, and the resulting white precipitate was filtered and washed with HC1 (0.1M, 20 ml) and distilled water (2x20 ml). The resulting white solid was dried under high vacuum for several days to afford Z-LysNTA as a white solid (2.68 g, 95% yield).
- Electrospray M/S m/z 397 (100%) (M+H + ), 398 (21%), 353 (30%), 792 (15%).
- ZLysNTA.TMSE 3 was synthesised using a procedure outlined by Gao et al. 2
- Substitute Sheet stirred at room temperature overnight. Distilled water (50 ml) was added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with dichloromethane (2x50 ml), and the organic extracts were combined and dried over anhydrous sodium carbonate. The mixture was filtered and all volatiles were removed under reduced pressure to afford a colourless oil. Purification by column chromatography on flash silica using a solvent gradient from dichloromethane to 5% methanol in dichloromethane afforded ZLysNTA.TMSE 3 as a colourless oil (0.75 g, 86%).
- Electrospray M/S m/z 719.4 (100%) (M+Na + )
- Substitute Sheet Rul 2 R ⁇ U multiplets 3.26-3.16 (10H, overlapping multiplets), 3.07 (IH, triplet), 1.85-1.30 (24H, overlapping multiplets, 12 x -CH 2 ), 0.97 (18H, overlapping multiplets, 9 x -CH 2 Si-), 0.05 (27H, s, 3 x -Si(CH 3 ) 3 ), 0.04 (54H, s, 6 x -Si(CH 3 ) 3 ) ppm.
- Electrospray M/S m/z 2054.3 (100%) (M+Na + ), 1038.8 (20%), 613.3 (36%)
- Electrospray M/S m/z 1151.4 (100%) (M+Na + ), 1129.2 (88%) (M+H + ), 1130.3 (56%) (M+2H + ), 1152.4 (53%) (M+Na + +H + ), 1165.3 (53%), 1143.3 (52%), 755.5 (50%), 907.2 (41%), 393.2 (26%).
- Electrospray M/S m/z 2019.8 (35%), ( +Na + ), 1997.8 (100%) (M + ).
- NTA TMSE 9 34 mg,0.0179 mmol was triturated with toluene, evaporated and dried under high vacuum.
- Trifluoroacetic acid (1 ml) was added and stirred under nitrogen atmosphere 0-5° C for 2 hours, then at room temperature overnight. The trifluoroacetic acid was evaporated and the residue was triturated with toluene again, evaporated and dried to afford t ⁇ NTA (20 mg, 100%).
- Gramicidin (75 mg, 0.0398 mmol) was dissolved in pyridine (0.5 ml) and succinic anhydride (20 mg, 0.200 mmol) was added. The mixture was stirred under nitrogen atmosphere at 50° C for 20 hours and evaporated. The crude product was passed down a sephadex LH-20 column in methanol, the eluate was evaporated and purified on a flash silica column using dichloromethane/methanol/water/acetic acid (400:50:4:1). The product was further purified by centrifuging with water. The water was decanted and the product was dried under high vacuum to give gramicidin succinate (53 mg, 67%).
- Gramicidin succinate (21 mg, 0.0105 mmol), N-hydroxysuccinamide (12 mg, 0.1042 mmol) and 4-dimethylamino pyridine (2.5 mg, 0.0204 mmol) were combined with distilled tetrahydrofuran (10 ml). With stirring under nitrogen dicyclohexylcarbodiimide (22 mg, 0.1066 mmol) was added. The mixture was heated to reflux for one hour. The mixture was evaporated and passed down a sephadex LH- 20 column in methanol. Appropriate fractions were evaporated and dried to give gramicidin succinate NHS (22 mg, 100%).
- Lysine tri NTA (20 mg, 0.0201 mmol) was dissolved in methanol (1 ml) and triethylamine (2 drops) was added to neutralise. Then gramicidin succinate NHS (15
- Gramicidin lysine 2XBOC (12 mg,0.0052 mmol) was triturated with toluene, evaporated and dried under high vacuum. Trifluoroacetic acid (1 ml) was added, evaporated under nitrogen and dried. Again toluene was added, evaporated and dried under high vacuum. The crude amine was dissolved in pyridine (0.5 ml) and reacted with succinic anhydride (2.6 mg, 0.0259mmol). The reaction mixture was stirred at room temperature for 20 hours. Pyridine was removed under high vacuum and the residue was passed down the sephadex LH-20 column in methanol. The product was further purified on a flash silica column eluted with methanol to give gAlysine 2X Succinate (10 mg, 83%).
- Substitute Sheet 0.0363mmol was added. The mixture was refluxed under nitrogen for 1 hour. The mixture was evaporated and purified on a sephadex LH-20 column in methanol. Appropriate fractions were evaporated and added to lysine tri NTA (8.5 mg, 0.0085 mmol). The mixture was stirred at room temperature for 18 hours. The reaction mixture was evaporated and purified on sephadex LH-20 in methanol (X2). Gramicidin lysine 2Xtri NTA (2.6 mg, 19%) was obtained (due to low solubility some compound was lost).
- Electrospray M/S m/z 1173.9 (100%), 2146.4 (25%) (M+Na + ).
- Trifluoroacetic acid (2 ml) was added to Biotin.triNTA.TMSE 9 (19 mg, 9 umol) at 0°C.
- the reaction mixture was stirred at 0°C for 3 hour, after which time all volatiles were removed under reduced pressure.
- Electrospray M/S m/z 1221.5 (100%) (M+H + ), 1243.4 (33%) (M+Na + ).
- Electrospray M/S m/z 1486.6 (100%) (M+H + ), 1508.8 (62%) (M+Na + ).
- the reaction mixture was added with chloroform (50 mL) and then washed successively with 40 mL portions of water (x2), 3% potassium carbonate (x2), water (x2), 5% HC1 (x2) and water (x2). (NB.
- the phase separation was extremely tedious due to emulsion formation at each of the successive wash. In order to improve the process an addition of methanol was necessary.
- the organic phases were combined and dried over sodium sulphate. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography. [Eluant; dichloromethane: acetone: methanol: ammonium hydroxide (8:5:5:3)] 122 mg of colourless waxy material was obtained.
- Substitute Sheet ( Rule 26) RO/AU 2X-Boc (420mg) was treated with TFA (5mL) for 20 mins under nitrogen atmosphere. TFA was removed under reduduced pressure and dried under high vacuum. This residue was then dissolved in 9% aqueous sodium carbonate solution (6mL) and the solution cooled to 0°C. Fmoc-NMS ester (purchased from CALBIOCHEM) (420mg) dissolved in DMF(3mL) was added into the above stirring solution at 0°C and stirred at RT for 30 mins. Water (lOOmL) was added and aqueous solution extracted with ethyl acetate (2x50mL) and organic extracts were discarded. Aqueous layer acidified with concentrated hydrochloric acid (2-3mL) and cooled in an ice bath during which a precipitate appeared. This precipitate was filtered and dried to give white powder (210mg).
- the Fmoc protected material (200mg) was dissolved in a solution of piperidine:DMF (20:80) stirred at room temperature for 10 minutes. DMF removed under reduced pressure and the crude material was purified by column chromatography (methanol :aqueous ammonia: DCm 10:2:88). Pure product was isolated as a colorless semi-solid (148mg).
- the NHS ester of this material was prepared by reaction of the acid (50mg) with NHS (8mg) in the presence of DCC (15mg) and DMAP (2.6mg) in CH 2 C1 2 (3ml) for 4h and purified by passage through a Sephadex LH-20 column eluting with methanol.
- SPR Surface Plasmon Resonance
- This Jl.triNTA chip was docked into a BIAcore 2000 machine and the pumps flushed and experiments performed using HBS/EDTA running buffer (50 mM HEPES, 300 mM NaCl. 50 ⁇ M EDTA, pH 8 0) at a flow rate of 40 ⁇ l/min at 21 °C Flow cell 2 (Fc2) was used as the test cell relative to the control Flow cell 1 (Fcl)
- running buffer containing 500 ⁇ M N ⁇ Cl 2 was injected through Fc2 only, which was then washed with running buffer for 5 min
- the protein of interest 100-600 nM
- Substitute Sheet 17 Liley, M., Keller, T.A., Duschl, C, Vogel, H., Langmuir, 1997, 13, 4190.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP8563A AUPP856399A0 (en) | 1999-02-08 | 1999-02-08 | Improved compounds for protein binding |
AUPP856399 | 1999-02-08 | ||
PCT/AU2000/000075 WO2000047548A1 (en) | 1999-02-08 | 2000-02-08 | Improved compounds for protein binding |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1150942A1 true EP1150942A1 (en) | 2001-11-07 |
EP1150942A4 EP1150942A4 (en) | 2003-02-12 |
Family
ID=3812765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00904701A Withdrawn EP1150942A4 (en) | 1999-02-08 | 2000-02-08 | Improved compounds for protein binding |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1150942A4 (en) |
JP (1) | JP2002536428A (en) |
CN (1) | CN1345301A (en) |
AU (1) | AUPP856399A0 (en) |
CA (1) | CA2341348A1 (en) |
WO (1) | WO2000047548A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6919333B2 (en) * | 2002-11-12 | 2005-07-19 | Rutgers, The State University Of New Jersey | Bis-transition-metal-chelate probes |
AU2002367810A1 (en) * | 2002-03-28 | 2003-11-10 | Rutgers, The State Of University Of New Jersey | Bis-transition-metal-chelate-probes |
DE10227599B4 (en) * | 2002-06-20 | 2005-04-28 | Proteome Factory Ag | Method and reagent for the specific identification and quantification of one or more proteins in a sample |
AU2004254295B2 (en) * | 2003-07-08 | 2010-05-27 | Tacnia Pty Ltd | Improvements in sensor chips |
AU2003903504A0 (en) | 2003-07-08 | 2003-07-24 | Johnson, Daniel | Improvements in sensor chips |
JP4970035B2 (en) * | 2003-08-21 | 2012-07-04 | リポテック・プロプライエタリー・リミテッド | Targeting dendritic cells in vivo |
US7371585B2 (en) | 2003-12-31 | 2008-05-13 | Genencor International, Inc. | Membranes incorporating recognition moieties |
JP2008508333A (en) * | 2004-08-05 | 2008-03-21 | ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン | Multivalent chelators for modification and organization of target molecules |
DE102004038134B4 (en) | 2004-08-05 | 2013-07-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Multivalent chelators for modifying and organizing target molecules, methods for their preparation and their use |
EP2015071A1 (en) | 2007-07-13 | 2009-01-14 | FUJIFILM Corporation | Carrier, process for producing same, bioreactor, and chip for surface plasmon resonance analysis |
US8137733B2 (en) | 2007-11-22 | 2012-03-20 | Fujifilm Corporation | Process for producing a carrier |
JP2010190891A (en) * | 2009-01-22 | 2010-09-02 | Fujifilm Corp | Carrier, method of manufacturing the same, and extraction operation instrument |
DE102010008417A1 (en) * | 2010-02-18 | 2011-08-18 | Johann Wolfgang Goethe-Universität Frankfurt am Main, 60323 | High affinity multivalent chelator compounds (MCHs) and their use for the structural and functional analysis of target molecules |
WO2013160453A2 (en) * | 2012-04-26 | 2013-10-31 | Iba Gmbh | Adapter molecule capable of reversibly equipping a fusion protein carrying an oligohistidine affinity tag with a further affinity tag and methods of using the same |
US11639929B2 (en) * | 2014-04-29 | 2023-05-02 | Yeda Research And Development Co. Ltd. | Universal histidine-tag binding compounds and methods of use thereof as fluorescent probes and sensors |
EP3137898B1 (en) * | 2014-04-29 | 2023-09-20 | Yeda Research and Development Co., Ltd. | Fluorescent molecular sensor for targeting changes in protein surfaces, and methods of use thereof |
CN110183672B (en) * | 2019-05-31 | 2021-07-09 | 天津大学 | PETX polymer, preparation method and three-dimensional thorn-shaped sensor interface |
CN113999279A (en) * | 2020-11-04 | 2022-02-01 | 中国药科大学 | Dumbbell type amphiphilic peptide dendrimer, synthesis and application of dendrimer as drug delivery system |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3158635A (en) * | 1959-03-18 | 1964-11-24 | Stauffer Chemical Co | Bis-adduction products and methods of preparing same |
US3700671A (en) * | 1967-05-15 | 1972-10-24 | Monacelli Walter J | Chelating compositions |
EP0243929A2 (en) * | 1986-04-30 | 1987-11-04 | Robin Ewart Offord | Polypeptide and protein derivatives and process for their preparation |
US5096946A (en) * | 1989-08-18 | 1992-03-17 | Rainer Norman B | Polymer product for the selective absorption of dissolved ions |
US5342604A (en) * | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
WO1996003646A1 (en) * | 1994-07-22 | 1996-02-08 | Akzo Nobel N.V. | Chelator idac-2 and method for purifying chelator conjugated compounds |
DE19505960A1 (en) * | 1995-02-21 | 1996-08-22 | Deutsches Krebsforsch | Conjugate for the individual dosage of drugs |
DE19518421A1 (en) * | 1995-05-19 | 1996-11-21 | Basf Ag | Aspartic acid oligomers and derivs. with high chelating capacity |
WO1999066780A2 (en) * | 1998-06-25 | 1999-12-29 | Smithkline Beecham Plc | Cinoxacin lanthanide chelates and their use as biomolecular probes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE462454B (en) * | 1988-11-10 | 1990-06-25 | Pharmacia Ab | METHOD FOR USE IN BIOSENSORS |
US5580527A (en) * | 1992-05-18 | 1996-12-03 | Moltech Corporation | Polymeric luminophores for sensing of oxygen |
DE4430023A1 (en) * | 1994-08-24 | 1996-02-29 | Boehringer Mannheim Gmbh | Electrochemical sensor |
DE4433980C2 (en) * | 1994-09-23 | 1996-08-22 | Boehringer Ingelheim Int | Process and biosensor hit for investigating the interaction of biomolecules by means of surface plasma resonance |
US5620850A (en) * | 1994-09-26 | 1997-04-15 | President And Fellows Of Harvard College | Molecular recognition at surfaces derivatized with self-assembled monolayers |
PT820483E (en) * | 1995-04-07 | 2001-03-30 | Mogens Havsteen Jakobsen | METHOD OF IMMOBILIZATION OF PHOTOCHEMICALS OF LIGANDS USING QUINONES |
DE19607279A1 (en) * | 1996-02-27 | 1997-08-28 | Bayer Ag | Membrane biosensors supported by solid bodies |
EP0917533A2 (en) * | 1996-07-03 | 1999-05-26 | President And Fellows Of Harvard College | Oligonucleotide linker and techniques involving immobilized and linked oligonucleotides |
-
1999
- 1999-02-08 AU AUPP8563A patent/AUPP856399A0/en not_active Abandoned
-
2000
- 2000-02-08 JP JP2000598469A patent/JP2002536428A/en active Pending
- 2000-02-08 EP EP00904701A patent/EP1150942A4/en not_active Withdrawn
- 2000-02-08 CN CN00803375A patent/CN1345301A/en active Pending
- 2000-02-08 WO PCT/AU2000/000075 patent/WO2000047548A1/en not_active Application Discontinuation
- 2000-02-08 CA CA002341348A patent/CA2341348A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3158635A (en) * | 1959-03-18 | 1964-11-24 | Stauffer Chemical Co | Bis-adduction products and methods of preparing same |
US3700671A (en) * | 1967-05-15 | 1972-10-24 | Monacelli Walter J | Chelating compositions |
EP0243929A2 (en) * | 1986-04-30 | 1987-11-04 | Robin Ewart Offord | Polypeptide and protein derivatives and process for their preparation |
US5342604A (en) * | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
US5096946A (en) * | 1989-08-18 | 1992-03-17 | Rainer Norman B | Polymer product for the selective absorption of dissolved ions |
WO1996003646A1 (en) * | 1994-07-22 | 1996-02-08 | Akzo Nobel N.V. | Chelator idac-2 and method for purifying chelator conjugated compounds |
DE19505960A1 (en) * | 1995-02-21 | 1996-08-22 | Deutsches Krebsforsch | Conjugate for the individual dosage of drugs |
DE19518421A1 (en) * | 1995-05-19 | 1996-11-21 | Basf Ag | Aspartic acid oligomers and derivs. with high chelating capacity |
WO1999066780A2 (en) * | 1998-06-25 | 1999-12-29 | Smithkline Beecham Plc | Cinoxacin lanthanide chelates and their use as biomolecular probes |
Non-Patent Citations (5)
Title |
---|
HOCHULI E ET AL: "NEW METAL CHELATE ADSORBENT SELECTIVE FOR PROTEINS AND PEPTIDES CONTAINING NEIGHBOURING HISTIDINE RESIDUES" JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 411, 1987, pages 177-184, XP002059738 ISSN: 0021-9673 * |
MICHAELIS, L. ET AL.: J. BIOL. CHEM., vol. 106, 1934, pages 331-341, XP001040686 * |
See also references of WO0047548A1 * |
TERCERO-MORENO, J.M. ET AL.: J. COORD. CHEM., vol. 35, 1995, pages 73-83, XP001040664 * |
YASHUNSKII V G ET AL: "SYNTHESIS, ACID-BASE CHARACTERISTICS, AND COMPLEX-FORMING PROPERTIES OF [[(2-HYDROXYTRIMETHYLENE)DINITRILO]TETRAKI S(ETHYLENEDINITRILLO)]-O CTAACETIC ACID" JOURNAL OF GENERAL CHEMISTRY USSR, CONSULTANTS BUREAU. NEW YORK, US, vol. 60, no. 2, 1990, pages 309-313, XP001109160 * |
Also Published As
Publication number | Publication date |
---|---|
AUPP856399A0 (en) | 1999-03-04 |
JP2002536428A (en) | 2002-10-29 |
CA2341348A1 (en) | 2000-08-17 |
EP1150942A4 (en) | 2003-02-12 |
CN1345301A (en) | 2002-04-17 |
WO2000047548A1 (en) | 2000-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1150942A1 (en) | Improved compounds for protein binding | |
US8580820B2 (en) | Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof | |
US5679807A (en) | Preparation of taxol and docetaxel through primary amines | |
JP2007161712A (en) | 6-monoacetylmorphine derivative useful for immunoassay | |
US6506928B1 (en) | Dendrimeric fullerene derivatives, process for their preparation, and use as neuroprotectants | |
Xu et al. | Calixarene amino acids; building blocks for calixarene peptides and peptide-dendrimers | |
EP0232693A2 (en) | Conjugates of vinblastine and its derivatives, process for their preparation and pharmaceutical compositions containing them | |
WO1997043274A1 (en) | Improved reservoir components | |
EP1538156A1 (en) | Versatile linker compound and ligand, and method for preparation thereof | |
JPWO2005077965A1 (en) | Glycoligand complex and protein analysis method using the ligand complex | |
JP2022518601A (en) | Preparation method of drug linker MC-MMAF for antibody drug conjugate and its intermediate | |
Brettreich et al. | Convergent Synthesis of 1→ 3 C-Branched Polyamide Dendrons | |
CA2195005C (en) | Multifunctional cross-linking reagents for hemoglobin, and cross-linked hemoglobin conjugates | |
CN113365969B (en) | Connector containing phthalic aldehyde and application thereof in preparation of antibody-drug conjugate | |
JPH06500077A (en) | Conjugate materials, reagents and novel polyethers | |
AU2648500A (en) | Improved compounds for protein binding | |
AU2004203380A1 (en) | Improved compounds for protein binding | |
EP0442372B1 (en) | Improved labeled haptens, process for their preparation and the use of these labeled haptens in immunoassays | |
JP3565350B2 (en) | Protecting or anchoring groups and their use | |
Hashimoto et al. | Preparation and biological properties of biotinylated PhTX derivatives | |
WO1992012122A1 (en) | N-protected aminoalkylaldehydes | |
US9968683B2 (en) | Method for conjugating molecules | |
US5432288A (en) | Derivatives of ryanodine and dehydroryanodine | |
US5679701A (en) | Derivatives of ryanodine and dehydroryanodine | |
US5510500A (en) | Derivatives of ryanodine and dehydroryanodine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010816 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20010815;LT PAYMENT 20010815;LV PAYMENT 20010815;MK PAYMENT 20010815;RO PAYMENT 20010815;SI PAYMENT 20010815 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AUSTRALIAN MEMBRANE AND BIOTECHNOLOGY RESEARCH INS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AMBRI LIMITED |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20030103 |
|
111L | Licence recorded |
Free format text: 0100 BIOSENSOR ENTREPRISES , LLC Effective date: 20030825 |
|
17Q | First examination report despatched |
Effective date: 20040312 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050901 |